Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer Patients-A Single-Center Case-Control Study

Overview

Journal Diseases

Date 2021 Nov 29

PMID 34842668

Citations 4

Authors

Flora Greta Petenyi

Tamas Garay

Dorottya Muhl

Blanka Izso

Adam Karaszi

Erika Borbenyi

Magdolna Herold

Zoltan Herold

Attila Marcell Szasz

Magdolna Dank

Affiliations

Soon will be listed here.

Abstract

Methods: A retrospective single-center case-control study was conducted with the inclusion of 78 inoperable PDAC patients. Age-, sex-, chemotherapy-, stage-, and ascites formation-matched patients were assigned to two equal groups based on the application of modulated electro-hyperthermia (mEHT). The EHY2030 mEHT device was used.

Results: A trend in favor of mEHT was found in overall survival ( = 0.1420). To further evaluate the potential beneficial effects of mEHT, the presence of distant metastasis or ascites in the patients' oncological history was investigated. Of note, mEHT treatment had a favorable effect on patients' overall survival in metastatic disease ( = 0.0154), while less abdominal fluid responded to the mEHT treatment in a more efficient way ( ≤ 0.0138).

Conclusion: mEHT treatment was associated with improved overall survival in PDAC in our single-center retrospective case-control study. The outcome measures encourage us to design a randomized prospective clinical study to further confirm the efficiency of mEHT in this patient cohort.

Citing Articles

Synergistic effects of 6-shogaol and hyperthermia on ACHN renal cancer cells: modulation of ROS and heat shock pro-teins in cancer therapy.

Ahn C, Baek S Front Pharmacol. 2025; 16:1522285.

PMID: 40051570 PMC: 11882530. DOI: 10.3389/fphar.2025.1522285.

Heat shock factor 1 inhibition enhances the effects of modulated electro hyperthermia in a triple negative breast cancer mouse model.

Viana P, Schvarcz C, Danics L, Besztercei B, Aloss K, Bokhari S Sci Rep. 2024; 14(1):8241.

PMID: 38589452 PMC: 11002009. DOI: 10.1038/s41598-024-57659-x.

Comparison of the effectiveness of integrative immunomodulatory treatments and conventional therapies on the survival of selected gastrointestinal cancer patients.

Kleef R, Dank M, Herold M, Agoston E, Lohinszky J, Martinek E Sci Rep. 2023; 13(1):20360.

PMID: 37990076 PMC: 10663566. DOI: 10.1038/s41598-023-47802-5.

The Clinical Validation of Modulated Electro-Hyperthermia (mEHT).

Lee S, Lorant G, Grand L, Szasz A Cancers (Basel). 2023; 15(18).

PMID: 37760538 PMC: 10526385. DOI: 10.3390/cancers15184569.

Hyperthermia combined with chemotherapy chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study.

Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca P World J Clin Oncol. 2023; 14(6):215-226.

PMID: 37398545 PMC: 10311475. DOI: 10.5306/wjco.v14.i6.215.

References

Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R . Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2012; 31(1):23-9. DOI: 10.1200/JCO.2012.44.4869. View

Iyikesici M . Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer. Complement Med Res. 2019; 27(1):31-39. DOI: 10.1159/000502135. View

Kakehi M, Ueda K, Mukojima T, Hiraoka M, Seto O, Akanuma A . Multi-institutional clinical studies on hyperthermia combined with radiotherapy or chemotherapy in advanced cancer of deep-seated organs. Int J Hyperthermia. 1990; 6(4):719-40. DOI: 10.3109/02656739009140820. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Hamazoe R, Maeta M, Murakami A, Yamashiro H, Kaibara N . Heating efficiency of radiofrequency capacitive hyperthermia for treatment of deep-seated tumors in the peritoneal cavity. J Surg Oncol. 1991; 48(3):176-9. DOI: 10.1002/jso.2930480307. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Kampinga H . Cell biological effects of hyperthermia alone or combined with radiation or drugs: a short introduction to newcomers in the field. Int J Hyperthermia. 2006; 22(3):191-6. DOI: 10.1080/02656730500532028. View

Rahib L, Smith B, Aizenberg R, Rosenzweig A, Fleshman J, Matrisian L . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(11):2913-21. DOI: 10.1158/0008-5472.CAN-14-0155. View

Busing F, Weaver B, Dubois S . 2 × 2 Tables: a note on Campbell's recommendation. Stat Med. 2015; 35(8):1354-8. DOI: 10.1002/sim.6808. View

10.

Robins H, Cohen J, SCHMITT C, Tutsch K, Feierabend C, Arzoomanian R . Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients. J Clin Oncol. 1993; 11(9):1787-94. DOI: 10.1200/JCO.1993.11.9.1787. View

11.

Deng Y, Tu H, Pierzynski J, Miller E, Gu X, Huang M . Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma. Eur J Cancer. 2018; 92:20-32. PMC: 7504973. DOI: 10.1016/j.ejca.2017.12.023. View

12.

Martin-Perez E, Dominguez-Munoz J, Botella-Romero F, Cerezo L, Matute Teresa F, Serrano T . Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. Clin Transl Oncol. 2020; 22(11):1963-1975. PMC: 7505812. DOI: 10.1007/s12094-020-02350-6. View

13.

Werthmann P, Inter P, Welsch T, Sturm A, Grutzmann R, Debus M . Long-term tumor-free survival in a metastatic pancreatic carcinoma patient with FOLFIRINOX/Mitomycin, high-dose, fever inducing Viscum album extracts and subsequent R0 resection: A case report. Medicine (Baltimore). 2018; 97(49):e13243. PMC: 6310555. DOI: 10.1097/MD.0000000000013243. View

14.

Rogers S, Datta N, Puric E, Timm O, Marder D, Khan S . The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas. Clin Transl Radiat Oncol. 2021; 27:109-113. PMC: 7868682. DOI: 10.1016/j.ctro.2021.01.008. View

15.

Von Hoff D, Ervin T, Arena F, Chiorean E, Infante J, Moore M . Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691-703. PMC: 4631139. DOI: 10.1056/NEJMoa1304369. View

16.

Rao W, Deng Z, Liu J . A review of hyperthermia combined with radiotherapy/chemotherapy on malignant tumors. Crit Rev Biomed Eng. 2010; 38(1):101-16. DOI: 10.1615/critrevbiomedeng.v38.i1.80. View

17.

Saif M . New Developments in the Treatment of Pancreatic Cancer: Highlights from the 44th ASCO Annual Virtual Meeting, May 29-31, 2020. JOP. 2020; 21(5):108-111. PMC: 7473328. View

18.

Szasz A, Minnaar C, Szentmartoni G, Szigeti G, Dank M . Review of the Clinical Evidences of Modulated Electro-Hyperthermia (mEHT) Method: An Update for the Practicing Oncologist. Front Oncol. 2019; 9:1012. PMC: 6837995. DOI: 10.3389/fonc.2019.01012. View

19.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

20.

Bakshandeh-Bath A, Stoltz A, Homann N, Wagner T, Stolting S, Peters S . Preclinical and clinical aspects of carboplatin and gemcitabine combined with whole-body hyperthermia for pancreatic adenocarcinoma. Anticancer Res. 2009; 29(8):3069-77. View